(Reuters) -The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Maryland healthcare professionals are concerned by the short supply of IV fluid caused by the fallout from Hurricane Helene ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer is looking to use AI in a Singapore initiative to shorten the drug discovery process. Read more at straitstimes.com.

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...